Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging technique aims to catch scleroderma inflammation before scarring sets in

NCT ID NCT07212959

Diagnosis Sponsor: Wuerzburg University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a type of PET scan called CXCR4-PET/CT can detect inflammation in people with systemic sclerosis (SSc), a disease that causes scarring in organs like the lungs. The scan uses a radioactive tracer to highlight active immune cells. The goal is to find inflammation early, before it turns into permanent fibrosis. Twelve adults with early SSc and lung scarring took part in this completed imaging study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
68Ga-Pentixafor (a radioactive tracer for PET imaging)
What this could lead to
If successful, this imaging method could help doctors detect inflammation early in systemic sclerosis, potentially preventing irreversible organ damage.
What could go wrong
This is a very small, completed study with only 12 participants, so results may not apply to all patients. It is an imaging test, not a treatment, so it cannot change the disease course on its own.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Jan 2024

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of SSc based on the 2013 ACR/EULAR criteria * Duration of disease less than 5 years (onset of the first non-Raynaud's symptom within the last 5 years) * Evidence of ILD on computed tomography * Patient's ability to understand the information provided * Patient of legal age Exclusion Criteria: * Following autologous stem cell transplantation * Presence of pulmonary hypertension * Contraindications for performing a PET/CT scan - Pregnancy * Breastfeeding * Allergies to 68Ga-Pentixafor * Patient's inability to understand and give informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Systemic sclerosis (SSC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic sclerosis (SSC)

Contacts and locations

Locations

  • University Hospital Würzburg

    Würzburg, Bavaria, 97078, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.